Skip Navigation


QJM Advance Access originally published online on September 6, 2006
QJM 2006 99(10):718-719; doi:10.1093/qjmed/hcl100
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
99/10/718    most recent
hcl100v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Arya, S.C.
Right arrow Articles by Agarwal, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arya, S.C.
Right arrow Articles by Agarwal, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Correspondence

Evaluating broad-spectrum antimicrobials

The first 10% of the full text of this article appears below.

Sir,

In a recent QJM paper, investigators at the Shaare Zedek Medical Center, Jerusalem studying the prospective utility of cefepime, piperacillin-tazobactam and meropenem recommended formal infectious disease consultation for their appropriate usage.1 Ideally, empirical treatment regimens with broad-spectrum and/or costly antimicrobials would be based . . . [Full Text of this Article]

S.C. Arya, N. Agarwal and S. Agarwal

Sant Parmanand Hospital
18 Alipore Road
Delhi 110054
India

email: subhashji@hotmail.com


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?